Form 4: TriSalus Life Sciences Insider Buys Shares

Mary T. Szela, CEO and President of TriSalus Life Sciences, Inc., acquired 39,682 shares of common stock.

Summary

• Mary T. Szela, CEO and President of TriSalus Life Sciences, Inc., and a Director, acquired 39,682 shares of common stock on May 15, 2026.
• The acquisition was made at a weighted average price of $2.59 per share, with individual transactions ranging from $2.48 to $2.62.
• This purchase was matched against prior sales of common stock to cover tax withholding obligations related to restricted stock units.
• Szela paid $27,573.70 to the Issuer to disgorge profits from a short-swing transaction, as required by Section 16(b) of the Securities Exchange Act of 1934.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly positive. While an insider purchase is generally a good sign, the primary driver appears to be compliance with Section 16(b) regulations, which involves returning profits from a short-swing trade. The actual investment aspect is secondary to the regulatory necessity.

Positives

• Insider purchase of common stock by a key executive (CEO, President, Director) indicates confidence in the company's future.
• The acquisition of 39,682 shares demonstrates a commitment to the company's equity.
• The weighted average purchase price of $2.59 suggests a potentially attractive entry point for the executive.

Negatives

• The transaction is characterized as a 'short-swing transaction' under Section 16(b), requiring disgorgement of profits.
• The reporting person had to pay $27,573.70 to the Issuer to settle the short-swing profit liability.
• Prior sales of stock were to satisfy tax withholding obligations, indicating potential cash flow needs or tax liabilities for insiders.

Risks

• Potential for further Section 16(b) implications if future transactions are not carefully managed.
• The need to sell shares for tax withholding could indicate pressure on insider liquidity or tax planning challenges.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a report of a past transaction.

Management Comments

• The Reporting Person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 39,682 shares at a weighted average price of $2.59, with the Reporting Person's sales of 4,358 shares of common stock at a price per share of $4.13 on March 11, 2026 and of 15,944 shares of common stock at a price per share of $3.85.
• The prior sales represented shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person, and did not represent discretionary sales by the Reporting Person.
• The Reporting Person paid $27,573.70 to the Issuer, representing the full amount of profit realized in connection with the short-swing transaction.
• The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.48 to $2.62 per share.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Industry Context

StockSavvy.ai notes that insider purchases, especially by C-suite executives and directors, are often viewed positively by the market as they signal a belief in the company's intrinsic value and future prospects. However, the context of this purchase, being tied to a Section 16(b) short-swing profit disgorgement, adds a layer of complexity, suggesting that while an investment was made, it was also a necessary step to rectify a prior regulatory issue.

Legal Proceedings

• The transaction is subject to Section 16(b) of the Securities Exchange Act of 1934, requiring the disgorgement of profits from short-swing transactions.

Stakeholder Impact

• Shareholders: The insider purchase may signal confidence, but the Section 16(b) compliance aspect tempers immediate positive sentiment. The disgorgement of profits means the company received funds that might otherwise have been retained by the insider.
• Management: Highlights the importance of strict adherence to insider trading regulations and the potential financial implications of non-compliance.
• Regulatory Bodies (SEC): The filing ensures compliance with reporting requirements under Section 16(a) and Section 16(b).

Next Steps

• The reporting person has undertaken to provide further details on share purchases at specific prices upon request.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, Form 4, Insider Trading, Beneficial Ownership, Common Stock, Section 16(b), Short-Swing Transaction, Mary T. Szela, CEO, President, Director